# Empagliflozin and Atrial Fibrillation Treatment

Study · id `cardio:ct-nct04583813` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04583813](<https://clinicaltrials.gov/study/NCT04583813>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04583813

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT04583813. Randomized; double masking; primary purpose treatment. Start 2021-09 (anticipated); primary completion 2024-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT04583813, source copy `cardio:ctgov-nct04583813-2021-04-02`, retrieved 2026-10-26)
- Planned start: 2021-09 (anticipated) (ClinicalTrials.gov record NCT04583813, source copy `cardio:ctgov-nct04583813-2021-04-02`, retrieved 2026-10-26)
- Primary completion: 2024-01 (anticipated) (ClinicalTrials.gov record NCT04583813, source copy `cardio:ctgov-nct04583813-2021-04-02`, retrieved 2026-10-26)
- Completion: 2024-04 (anticipated) (ClinicalTrials.gov record NCT04583813, source copy `cardio:ctgov-nct04583813-2021-04-02`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT04583813, source copy `cardio:ctgov-nct04583813-2021-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04583813-2021-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin and Atrial Fibrillation Treatment
- Acronym: EMPA-AF
- Condition: Atrial Fibrillation
- Condition: Heart Failure
- Condition: Obesity
- Condition: Diabetes Mellitus
- Intervention (Drug): Empagliflozin
- Intervention (Other): Placebo
- Lead sponsor: Miulli General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: f90801a5150deacfa25cb4ed98618c4af7a2c5bdf261b366792357235619b60d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
